Africa: South Africa's Next HIV Battle Isn't About Science, It's About Access

What the report says

AllAfrica reports that South Africa is emerging as a key test case for expanding access to lenacapavir, a twice-yearly injectable HIV prevention medicine that researchers view as a major advance after daily PrEP. The report, filed from the AIDS 2026 conference in Rio de Janeiro, says South Africa introduced lenacapavir into public HIV prevention services in June, initially across six provinces: Gauteng, KwaZulu-Natal, the Eastern Cape, Mpumalanga, North West and the Western Cape.

The access debate is significant because South Africa remains heavily affected by HIV, with AllAfrica citing about eight million people living with the virus and roughly 160,000 new infections each year. The article highlights adolescent girls and young women as a priority group, noting that many remain at high risk and may benefit from prevention options that do not require daily pill-taking or frequent clinic attendance.

At the International AIDS Society conference, scientists, policymakers, drugmakers and advocates discussed trial findings, implementation lessons and future prevention tools. IAS president Beatriz Grinsztejn said scientific advances will matter only if they reach those most in need, while conference delegates raised concerns about shrinking international health funding and pressure on U.S.-backed HIV programmes. The report says generic versions of lenacapavir are still expected to be at least a year away.

AllAfrica also describes ongoing implementation research in South Africa, including the ALIGN study led by Elzette Rousseau of the Desmond Tutu Health Foundation. That study is enrolling young people through public facilities and mobile clinics to assess real-world choices among daily oral PrEP, injectable cabotegravir and lenacapavir. The central challenge, the report suggests, is no longer whether the science works, but whether health systems can deliver it equitably and sustainably.